Nervous Disorder TRIZ Cases

Pre-implantation factor peptides counteract progressive inflammatory responses and systemic immune activation in traumatic brain injury.

Lentiviral vectors deliver Oct4, Sox2, and Nanog to reprogram primate somatic cells, eliminating embryonic tissue requirements and reducing rejection risks.

Formula I pyrrolotriazine compounds inhibit AAK1 kinase activity, addressing off-target effects of existing treatments.

Adjusting gamma hydroxybutyrate dosage prevents valproate or diclofenac from causing unsafe efficacy shifts.

Segment full-length AARS proteins to uncover masked extracellular signaling functions, enabling targeted therapeutic and diagnostic applications.

Cyclized deuterized therapeutic peptides cross the blood-brain barrier to deliver neuroprotective actions while minimizing immunogenicity.

Systemic antibody administration restricts viral biodistribution to target tissues, resolving toxicity and transduction efficiency contradictions.

7H-Pyrrolo[2,3-d]pyrimidine compounds antagonize DYRK1A to reduce cancer cell proliferation.

Tethered hydrogel matrix seeded with tension-generating stem cells self-aligns to form a structured neural repair scaffold.

Merging muscadine pomace and Japanese knotweed extracts overcomes sub-optimal bioavailability while enhancing cellular aging inhibition.

Cyclic peptides replace complex monoclonal antibodies to reduce manufacturing difficulty while maintaining therapeutic efficacy for gastrointestinal conditions.

Amide-modified L-dopa derivatives prevent neuronal death by maintaining stable dopamine levels and reducing oxidative stress.

Multimeric peptide vectors transport therapeutic agents across the blood-brain barrier, overcoming permeability limits for central nervous system treatments.

Subcutaneous botulinum toxin injection targets specific nerves to reduce excessive neuroexcitatory chemical production in autism patients.

Compounds enhance mitochondrial proteostasis to reduce amyloid-beta aggregation, addressing dysfunction that limits current therapies.

Lentivirus vectors deliver shRNA sequences that continuously transcribe siRNA, overcoming the short duration and high cost of direct siRNA introduction.

Engineered peptides bind beta-amyloid proteins to resolve Alzheimer's pathology while bypassing current symptom-only treatments.

Adeno-associated viral vectors deliver progranulin transgenes directly to the central nervous system.

Mixing xanthohumol extracts with transition metal salts precipitates solids above 90% purity, avoiding complex chromatography systems.

Specific aryl substituents in M1 PAM compounds improve brain penetration while minimizing cholinergic side effects like hypersalivation.

Phenoxytriazole compounds modulate gamma-secretase activity to reduce neurotoxic Aβ42 peptides and amyloid plaque formation.

A pharmaceutical composition combining Angelica gigas Nakai extract with broccoli extract to protect nerve cells.

Anti-Ovr110 antibodies bind Ovr110 antigens on tumor cells, resolving specificity limits in ovarian and breast cancer diagnostics.

A gene construct encoding insulin utilizes a CAG promoter to drive robust expression within the central nervous system.

Composite wafer with naloxone prevents parenteral extraction and diversion while maintaining therapeutic efficacy.

Administering GPR139 antagonists reduces dependence and withdrawal symptoms while enhancing opioid efficacy.

Anti-IL-21 monoclonal antibodies bind human IL-21 antigens, neutralizing protein activity to inhibit autoimmune disorders.

Levosimendan improves functional status in ALS patients by altering calcium sensitivity to boost muscle strength despite disease progression.

Ternary metal complexes of valproic acid with diimines or diamines reduce hepatotoxicity while maintaining therapeutic effectiveness.

Inhibiting soluble epoxide hydrolase accumulates epoxy-fatty acids, reducing inflammation and relapse risk in depression treatment.

Pharmaceutical agents increase NF1 protein concentration to treat neurofibromatosis type 1 haploinsufficiency without causing cytotoxicity.

Antibody binding GPIIIa49-66 inhibits platelet micro-clots, reducing vascular damage and cognitive decline in cerebral amyloid angiopathy.

CRISPR-edited hematopoietic stem cells express progranulin to repopulate microglia and address frontotemporal dementia pathophysiology.

Microbiota Transfer Therapy rebalance gut flora via fecal transfer, resolving the trade-off between treating core ASD symptoms and gastrointestinal issues.

Attaching oligosaccharide chains to phenothiazine reduces venous thrombosis and local tissue irritation while maintaining systemic efficacy.

Multi-herbal composition reduces oxidative stress and inflammation in the brain, addressing blood-brain barrier penetration limits.

Segmented C5aR1 modulators block pathogenic effects while preserving complement pathways to reduce infection risks.

Liquid pharmaceutical composition with emulsion forming excipients maintains stable mean particle diameter under ambient conditions.

Antibodies with modified Fc polypeptides resolve blood-brain barrier trade-offs to inhibit amyloid-beta production.

Fluorophores with large Stokes shifts separate excitation and emission wavelengths, eliminating spectral overlap interference in biological imaging.

Modifying creatine derivatives with amide bonds reduces adverse effects while enhancing neuroprotective activity.